Celldex Therapeutics (CLDX)

Mar 4, 2025, 8:01 AM EST - 8 days ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 9 days ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 11 days ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 13 days ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Dec 19, 2024, 8:01 AM EST - 2 months ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Nov 20, 2024, 8:01 AM EST - 4 months ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 6, 2024, 4:01 PM EST - 4 months ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 3:14 PM EST - 4 months ago

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market

Oct 26, 2024, 5:43 PM EDT - 4 months ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 4 months ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Sep 25, 2024, 10:45 AM EDT - 6 months ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 16, 2024, 8:01 AM EDT - 6 months ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 7 months ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 29, 2024, 4:01 PM EDT - 8 months ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 8 months ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 10 months ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 10 months ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 10 months ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 10, 2024, 10:44 AM EDT - 10 months ago

Celldex Therapeutics: Rising High, With Room For Further Growth

May 6, 2024, 4:01 PM EDT - 11 months ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 17, 2024, 8:01 AM EDT - 11 months ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 1 year ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 1 year ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Mar 5, 2024, 10:10 AM EST - 1 year ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 29, 2024, 9:14 PM EST - 1 year ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 1 year ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 26, 2024, 7:01 AM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 24, 2024, 2:05 PM EST - 1 year ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 6, 2024, 4:01 PM EST - 1 year ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:01 AM EST - 1 year ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Jan 29, 2024, 10:45 AM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 3

CFR CHRD CROX CTO GLW LEU SCHW

Jan 26, 2024, 5:30 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 2

ANET BAX BIP BLK BP CCJ CSTE

Nov 27, 2023, 4:15 PM EST - 1 year ago

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Nov 8, 2023, 3:22 PM EST - 1 year ago

Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic

Nov 7, 2023, 11:15 PM EST - 1 year ago

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 8:15 AM EST - 1 year ago

Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions

Nov 6, 2023, 6:30 AM EST - 1 year ago

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Nov 5, 2023, 3:00 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

Nov 2, 2023, 4:01 PM EDT - 1 year ago

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 26, 2023, 7:01 AM EDT - 1 year ago

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

Sep 25, 2023, 8:31 AM EDT - 1 year ago

Celldex Therapeutics to Present at Cantor Global Healthcare Conference

Aug 11, 2023, 8:41 AM EDT - 1 year ago

Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 8:01 AM EDT - 1 year ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jul 6, 2023, 8:01 AM EDT - 1 year ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Jun 10, 2023, 10:45 AM EDT - 1 year ago

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Jun 8, 2023, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

May 31, 2023, 8:01 AM EDT - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies

May 18, 2023, 11:27 AM EDT - 1 year ago

Celldex Therapeutics: Revolutionizing Cancer Care With Innovative Immunotherapies

May 15, 2023, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™